The following search results are from Street Authority's public research only. Please Log In to search your premium services.

Results

Preparing a company for its public debut on the stock market is a long and arduous process. The numbers need to be checked and checked again, dozens of meetings with potential investors need to be arranged, and a virtual mountain of paperwork needs to be reviewed by regulators. So when… Read More

Investing in smaller companies can offer individual investors many important advantages. Perhaps the most important of all is that these companies can grow very quickly, since it doesn’t take much for new sales and profits to make a big impact on overall growth. Many stocks with small market capitalizations also… Read More

The market’s rough patch has recently knocked many stocks from their 52-week highs. Even the companies that are performing well are drifting ever lower, but the companies that have dared to stumble this spring are really taking a beating. One false move and they wake up to a share price … Read More

There’s a drama unfolding in the health care field that is as dramatic as the daytime soap operas. Lots of “he said, she said” has been tossed around, and just to add a little spice, a “bete noire” has also appeared on the scene to cause trouble. If this drama plays out a certain way, then shareholders of one or two of the companies involved may see a big windfall. The drama began back in 2006 when little-known Pharmathene (NYSE: PIP) sued Siga Technologies (Nasdaq: SIGA) for damages stemming from a broken business deal. Pharmathene had loaned… Read More

There’s a drama unfolding in the health care field that is as dramatic as the daytime soap operas. Lots of “he said, she said” has been tossed around, and just to add a little spice, a “bete noire” has also appeared on the scene to cause trouble. If this drama plays out a certain way, then shareholders of one or two of the companies involved may see a big windfall. The drama began back in 2006 when little-known Pharmathene (NYSE: PIP) sued Siga Technologies (Nasdaq: SIGA) for damages stemming from a broken business deal. Pharmathene had loaned Siga money to fund research into a vaccination against smallpox. The loan was presumed to be an interim step before the two firms eventually merged. At a minimum, Pharmathene hoped to at least be granted rights to Siga’s drug, known as ST-246. The two firms had even drawn up documents that appear to imply a merger discussion was the eventual expected result. Siga appeared to eventually lose interest in any deal, figuring that it no longer needed Pharmathene’s stronger balance sheet to help fund the… Read More

#-ad_banner-#When President Obama’s armored limousine got stuck in Ireland this May as it exited the U.S. embassy, it was this towing company’s equipment that freed his vehicle, known affectionately as “The Beast.” Since receiving the president’s nod, Miller Industries (NYSE: MLR) — the world’s leading towing and… Read More